• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Trump nominates pharma insider Azar to lead HHS

Trump nominates pharma insider Azar to lead HHS

November 13, 2017 By Brad Perriello

Alex AzarThe Trump administration today nominated Alex Azar, who spent nearly 10 years at Eli Lilly (NYSE:LLY) after working in the second Bush administration, as secretary of the U.S. Health & Human Services Dept.

The former HHS head, Dr. Tom Price, resigned in September after days of fending off criticism over chartered flights he took on the public dime. Price racked up roughly $1 million in private and government air travel in just seven months, according to Politico.

“It’s a great pick for where the agency is right now,” Lanhee Chen, who worked with Azar on Mitt Romney’s 2012 presidential campaign, told the website. “I don’t think anybody can question his credentials from an experience perspective.”

“As both a former HHS deputy secretary and general counsel, together with his private-sector experience, Alex Azar has the knowledge, expertise, and leadership to oversee our Nation’s health response,” added AIDS Institute deputy executive director Carl Schmid.

“On behalf of AdvaMed and our member companies, I want to personally congratulate Alex Azar on his nomination as secretary of HHS. The president has made a smart choice; Alex is a tested leader in the hard-fought battles to advance health care within the department and across the country. I saw that leadership and character firsthand when I served with Alex at HHS. His expertise across a broad spectrum of issues – from public health to medical technology and beyond – will serve the nation well,” Scott Whitaker, CEO of the Advanced Medical Technology Assn., said in prepared remarks. “These are challenging times for national health policy, and Alex has a full understanding of what it will take to address those issues and meet the high standard of quality care Americans deserve. He also appreciates that, to meet our goals, we need to foster an environment that continues to put innovation at the vanguard of health care delivery.

“I urge the Senate to confirm Alex quickly, and pledge our support in helping him and the Department fulfill its mission,” Whitaker said.

Democrats, however, questioned Azar’s ability to distance himself from the pharma industry.

“All these drug corporations are jacking up prices because Washington isn’t doing its job to oversee them, and so I have great concerns,” Sen. Tammy Baldwin (D-Wis.) told Politico. “I’ll look at it when it officially comes to us, but I’m very disquieted.”

“They’ve also said they’re going to drain the swamp and crack down on Wall Street,” added Sen. Patrick Leahy (D-Vt.). “You’ve got the rhetoric. Let’s see what the reality is.”

“I would hope people would evaluate him based on the entirety of his career,” Chen told the website. “It’s politics, so you can imagine how people might use his background against him. But I hope that they don’t.”

Filed Under: Wall Street Beat Tagged With: Dept. of Health & Human Services (HHS), Personnel Moves

More recent news

  • Medtronic earns CE mark for redo TAVI procedure
  • Natus Neuro launches BrainWatch AI-driven, point-of-care EEG
  • Boston Scientific has positive real-world Acurate Prime TAVI data
  • Johnson & Johnson MedTech launches ultrasound catheter for imaging in cardiac ablation procedures
  • Onward reports more successful BCI implants

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy